ARENA PHARMACEUTICALS INC
DelistedCIK 1080709fmd_1F6J6YYB9728B683AYHWC6D5N4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Dec 31, 2021, 49 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 28 | 81 | 37 | 13 | 92 | 21 | 18 | 806 | 0 | 0 |
| Cost of revenue | 0 | 2 | 6 | 9 | 9 | – | – | – | – | – |
| Gross profit | 28 | 80 | 31 | 5 | 83 | – | – | – | – | – |
| Research and development | 54 | 66 | 100 | 83 | 64 | 71 | 115 | 231 | 324 | 420 |
| Selling, general and administrative | – | – | – | – | – | – | 45 | 78 | 103 | 126 |
| Operating income | (57) | (23) | (105) | (104) | (5) | (92) | (145) | 483 | (427) | (624) |
| Interest expense | 9 | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 4 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 27 | 11 | 1 |
| Other non-operating income (expense) | (28) | 4 | 45 | (7) | (7) | (4) | 6 | 25 | 22 | 8 |
| Income before taxes | (85) | (19) | (61) | (108) | (12) | (96) | (139) | 508 | (405) | (616) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (110) | 110 | 0 | 0 |
| Net income from continuing operations | (85) | (19) | (61) | (111) | (12) | (96) | (29) | 398 | (405) | (616) |
| Net income | (85) | (19) | (61) | (108) | (23) | (91) | (29) | 398 | (405) | (616) |
| Net income to common shareholders | (88) | (19) | (61) | – | – | – | – | – | – | – |